Rare Diseases >> Abstract Details   Alleviating Symptoms of Th2-Like Cytokine Mediated Disorders by Reducing IL-13 Receptor-Expressing Cells in the Respiratory Tract Description of Invention: This invention relates to the alleviation of symptoms of Th2-like cytokine mediated disorders, such as allergy, asthma, and to hyperinflammatory responses in the respiratory tract to infectious diseases and parasitic infections, including tuberculosis, schistosomiasis, leishmania, and filariasis. This invention claims a variety of methods and uses of a chimeric molecule comprising a toxic moiety and a targeting moiety that specifically binds to a cell surface receptor for IL-13, to alleviate symptoms of a variety of respiratory disorders. This method has been proven successful in various mouse models in vivo. Inventors: Raj K. Puri et al. (FDA) Patent Status: DHHS Reference No. E-296-2001/0 -- U.S. Provisional Application No. 60/337,179 filed 04 Dec 2001 PCT Application No. PCT/US02/00616 filed 28 Feb 2002, which published as WO 03/047632 on 12 Jun 2003 U.S. Patent Application No. 10/497,804 filed 04 Jun 2004 Portfolios: Internal Medicine Internal Medicine-Therapeutics-Anti-Inflammatory (including Autoimmune) Internal Medicine-Therapeutics For Additional Information Please Contact: David A. Lambertson Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd, Suite 325 Rockville, MD 20852-3804 Phone: (301)435-4632 Email: lambertsond@mail.nih.gov Fax: (301) 402-0220 Web Ref: 679 Last Updated On: 11/02